Global partnership to accelerate life science commercialisation

Biointelect, a leading life science consulting firm, and CR2O, a premier contract research organisation, have joined forces to offer enhanced end-to-end commercialisation solutions globally. The strategic partnership expands geographical reach and provides comprehensive strategic advice and clinical trial capabilities to clients in Australia, Europe, and the US.

CR2O, headquartered in the Netherlands, will extend Biointelect's capabilities by introducing clinical trial expertise across the European Union and Australia. In return, CR2O gains access to Biointelect's strategic product development consultancy and commercialisation proficiency.

This collaboration positions Biointelect and CR2O as frontrunners in delivering innovative end-to-end commercialisation solutions, streamlining project work through every stage of the development cycle.

Leah Goodman, CEO of Biointelect, expressed confidence that the partnership will fortify clients' trust and enhance their overall experience, focusing on performance and goal achievement. She highlighted the alliance's potential to yield greater returns for clients across the entire innovation journey.

CR2O CEO Hadil Es-Sbai emphasised the strategic collaboration's strength in providing advanced end-to-end commercialisation solutions. Leveraging established relationships and insights, the partnership aims to de-risk the complex journey from bench to bedside for pharmaceutical and biotechnology clients.

The partnership has already attracted interest from universities, government bodies, and life science companies seeking comprehensive, tailored solutions. With shared values underpinning their success, Biointelect and CR2O are poised to leverage their track records in bringing life science innovations to market efficiently.